Gingival crevicular fluid levels of human beta-defensin-1 in type 2 diabetes mellitus and periodontitis

Yılmaz, Doğukan; Çağlayan, Feriha; Büber, Esra; Könönen, Eija; Aksoy, Yasemin; Gürsoy, Ulvi Kahraman; Güncü, Güliz N.

doi:10.1007/s00784-018-2469-z

Cited by 12 publications

(10 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is well known the biunivocal association between periodontal disease and diabetes and pathophysiological mechanism related to immune functioning but is an under-recognized clinical problem [ 39 , 52 , 53 , 54 , 55 , 56 , 57 ]. Non-surgical periodontal treatment is associated with the reduction of 0.4% glycate hemoglobin (HbA1c) approximately [ 10 , 58 , 59 , 60 ]. The concept of periodontitis as “the sixth complication of diabetes” has been popularized by Loe in 1993 [ 49 ], who firstly demonstrated that the prevalence of periodontal disease was three times higher among type II diabetic persons compared with the nondiabetic [ 39 , 52 , 53 ].…”

Section: Discussionmentioning

confidence: 99%

Inflammatory Status and Glycemic Control Level of Patients with Type 2 Diabetes and Periodontitis: A Randomized Clinical Trial

Rapone

Ferrara

Corsalini

et al. 2021

IJERPH

View full text Add to dashboard Cite

Background: Based on the holistic approach to prevention diabetic disease, the role of periodontal inflammation in type 2 diabetes mellitus (T2DM) is under intensive scrutiny. Data from clinical trials have shown benefit from a periodontal therapy in providing patients with type 2 diabetes improvement despite relatively disappointing long-terms response rates. The aim of this study was to investigate the short-term glycemic control level and systemic inflammatory status after periodontal therapy. Methods: This was a randomized trial with a 6-months follow-up. Participants aged 56.4 ± 7.9 years with diagnosed type 2 diabetes and periodontitis were enrolled. Among the 187 type 2 diabetic patients, 93 were randomly assigned to receive non-surgical periodontal treatment immediately and 94 to receive the delayed treatment. Within and between groups comparison was done during the study period, and the differences between groups were assessed. Results: The difference between HbA1c values at baseline (Mdn = 7.7) and 6 months after non-surgical periodontal treatment (Mdn = 7.2) was statistically significant, U = 3174.5, p = 0.012, r = 0.187. However, although technically a positive correlation, the relationship between the glycated hemoglobin value and periodontal variables was weak. The differences between both the groups over 6 months were not statistically considerable, failing to reach statistical significance. At 6 months the difference between groups about the C-reactive protein (CRP) levels was statistically significant, U=1839.5, p = 0, r = 0.472, with a lower concentration for the intervention group. Furthermore, the intervention group showed a statistically significant difference between baseline and 6 months evaluation (U = 2606.5, p = 0, r = 0.308). Conclusions: The periodontal intervention potentially may allow individuals with type 2 diabetes to improve glycemic control and CRP concentrations, and diabetes alters the periodontal status.

show abstract

Section: Discussionmentioning

confidence: 99%

Inflammatory Status and Glycemic Control Level of Patients with Type 2 Diabetes and Periodontitis: A Randomized Clinical Trial

Rapone

Ferrara

Corsalini

et al. 2021

IJERPH

View full text Add to dashboard Cite

show abstract

“…Human beta‐defensins (hBDs) are small, cysteine‐rich cationic peptides with bi‐directional regulatory relations to the adaptive immune system, angiogenesis, and wound healing (Suarez‐Carmona, Hubert, Delvenne, & Herfs, ). Gingival hBDs are produced by epithelial cells (Gomes & Fernandes, ) and are released into saliva (Gürsoy et al, ) and gingival crevicular fluid (Ertugrul et al, ; Yilmaz et al, ). While hBD‐1 is secreted constitutively in periodontal tissues, hBD‐2 and hBD‐3 secretions are activated by bacterial or inflammatory stimuli (Ganz, ).…”

Section: Introductionmentioning

confidence: 99%

Gingival tissue human beta‐defensin levels in relation to infection and inflammation

Özdemir

Çağlayan

Bikker

et al. 2020

J Clinic Periodontology

Self Cite

View full text Add to dashboard Cite

Aim To profile gingival tissue levels of human beta‐defensin (hBD)‐2 and hBD‐3 in relation to gingival inflammation, Th17‐related cytokine concentrations, Porphyromonas gingivalis counts, and gingipain and total protease activities. Materials and Methods Gingival tissue and subgingival plaque samples were collected from 21 periodontitis patients including 48 periodontal pocket sites with marginal, mild, or moderate to severe inflammation. hBD levels were determined by immunodetection, P. gingivalis counts with real‐time polymerase chain reaction, protease activities with fluorogenic substrates, and cytokine concentrations with Luminex technique. Data were statistically analysed using Kruskal–Wallis and Mann–Whitney U tests and Spearman correlation coefficients. Results Subgingival plaque counts of P. gingivalis (p = .001) and gingipain activity (p < .001), as well as interleukin (IL)‐1β (p = .012), IL‐10 (p = .024), IL‐17A (p = .002), IL‐17F (p = .006), and IL‐23 (p = .036) concentrations were elevated in severely inflamed sites, whereas no change was observed in hBD‐2 and hBD‐3 levels. Negative correlations were found between protease activity and hBD‐2 (p = .033) and hBD‐3(p = .003) levels. Conclusions Shift in gingival inflammation from marginal to mild stage is related to elevations in subgingival plaque P. gingivalis counts and gingipain activity, but not to tissue hBD levels. Negative correlations between hBDs and total protease activity suggest the degradation of these antimicrobial peptides in progressed inflammation.

show abstract

“…From a total of 12 studies, 10 were observational studies (6 cross-sectional [ 30 , 31 , 32 , 33 , 34 , 35 ] and four case-control [ 36 , 37 , 38 , 39 ]), 1 was an animal study [ 40 ], and 1 was an in vitro study [ 41 ]. Different fluids/tissues were used for the HDPs’ analysis, including GCF [ 30 , 31 , 34 , 36 , 37 , 38 ], saliva [ 33 , 35 , 39 ], GT [ 32 ], and human oral epithelial cells [ 41 ]. However, one study [ 40 ] used both blood and GT for the analysis.…”

Section: Resultsmentioning

confidence: 99%

Host Defence Peptides in Diabetes Mellitus Type 2 Patients with Periodontal Disease. A Systematic Review

et al. 2021

View full text Add to dashboard Cite

The aim of the study was to critically assess and review the latest evidence relating the associations between host defence peptides (HDPs), periodontal diseases (PD) and diabetes mellitus type 2 (DM2). To explore studies on HDPs, periodontal disease, and DM2, researchers utilised specific key phrases to search the electronic databases PubMed (National Library of Medicine), Embase (Ovid), Medline (EBSCO), and Dentistry and Oral Sciences (EBSCO). Quality assessment was conducted by means of the Newcastle Ottawa scale and the Systematic Review Centre for Laboratory Animal Experimentation (SYRCLE) tool. Following a thorough screening process, a total of 12 papers (4 case-control, 6 cross-sectional, 1 animal, and 1 in vitro) fulfilled the selection criteria and were included. The majority of research found that HDPs were upregulated in DM2 patients with PD. Three investigations, however, found that HDPs were downregulated in DM2 patients with PD. HDPs play a part in the pathophysiology of PD and DM2. Nonetheless, more human, animal and laboratory investigations are needed to fully understand validation of the link, as the evidence is limited. Understanding HDPs as common moderators is critical, aimed at unlocking their potential as therapeutic and diagnostic agents.

show abstract

Gingival crevicular fluid levels of human beta-defensin-1 in type 2 diabetes mellitus and periodontitis

Abstract: The altered levels of hBD-1 in GCF of diabetics might be associated with the susceptibility of diabetics to periodontitis.

Cited by 12 publications

References 32 publications

Inflammatory Status and Glycemic Control Level of Patients with Type 2 Diabetes and Periodontitis: A Randomized Clinical Trial

Inflammatory Status and Glycemic Control Level of Patients with Type 2 Diabetes and Periodontitis: A Randomized Clinical Trial

Gingival tissue human beta‐defensin levels in relation to infection and inflammation

Host Defence Peptides in Diabetes Mellitus Type 2 Patients with Periodontal Disease. A Systematic Review

Contact Info

Product

Resources

About